The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma.
 
Carissa Ellen Chu
No Relationships to Disclose
 
Manuel De Jesus Escano
No Relationships to Disclose
 
Wesley Yip
No Relationships to Disclose
 
Song Jiang
No Relationships to Disclose
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech; PAIGE.AI
 
Alvin C. Goh
No Relationships to Disclose
 
Guido Dalbagni
No Relationships to Disclose
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Olympus
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Loxo; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Lilly; Pfizer; QED Therapeutics; Scorpion Therapeutics; Syros Pharmaceuticals; Vividion Therapeutics
 
Eugene J. Pietzak
Honoraria - UpToDate
Consulting or Advisory Role - Chugai Pharma; Janssen; Merck; QED Therapeutics